Search

Search Results
Results 141 - 150 of 256 for Myasthenia gravis
  • NIH grants boost rare diseases research efforts
    News - 4 Oct 2019
    Of an estimated 6,500 to 7,000 known rare diseases, only a fraction - maybe 5% - have U.S. Food and Drug Administration-approved treatments.
  • Meda publishes 2009 year-end report
    News - 16 Feb 2010
    “The Meda Group expects to achieve sales of about SEK 13,000 million and an EBITDA of about SEK 4,200 million for full-year 2009.”
  • LFB completes conversion of all acquired preferred stock
    News - 9 Jan 2010
    GTC Biotherapeutics, Inc. announced that LFB Biotechnologies, a wholly owned subsidiary of LFB S.A. (Laboratoire Français du Fractionnement et des Biotechnologies S.A., Les Ulis, France) and a...
  • DBL Amikacin Injection
    Drug - 4 Dec 2025
    Consumer Medicine Information (CMI) about DBL Amikacin Injection intended for persons living in Australia.
  • Tobramycin Viatris
    Drug - 2 Dec 2025
    Consumer Medicine Information (CMI) about Tobramycin Viatris intended for persons living in Australia.
  • DBL Tobramycin Injection
    Drug - 6 Nov 2025
    Consumer Medicine Information (CMI) about DBL Tobramycin Injection intended for persons living in Australia.
  • Tobramycin PF
    Drug - 6 Nov 2025
    Consumer Medicine Information (CMI) about Tobramycin PF intended for persons living in Australia.
  • Ditropan
    Drug - 14 Nov 2024
    Consumer Medicine Information (CMI) about Ditropan intended for persons living in Australia.
  • Defense department health plan cuts its pharmacy network by nearly 15,000 outlets
    News - 8 Nov 2022
    Doris Spatz takes a once-a-day pill, Kisqali, to keep her metastatic breast cancer in check. As a patient in the Defense Department health system, she can fill routine prescriptions at a military...
  • Persantin
    Drug - 17 Feb 2021
    Consumer Medicine Information (CMI) about Persantin intended for persons living in Australia.

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback